Informações de Longeveron Inc

Mais detalhes de Longeveron Inc Empresa

Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.



Código da empresaLGVN

Nome da EmpresaLongeveron Inc

Data de listagemFeb 12, 2021

CEOMr. Wa'el Hashad

Número de funcionários25

Tipo de títulosOrdinary Share

Fim do ano fiscalFeb 12

Endereço1951 NW 7th Ave

CidadeMIAMI

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal33136

Telefone13053027158

Sitehttps://www.longeveron.com/

Código da empresaLGVN

Data de listagemFeb 12, 2021

CEOMr. Wa'el Hashad

Executivos da empresa Longeveron Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Joshua M. Hare, M.D.

Executive Chairman of the Board, Co-Founder, Chief Science Officer

253.07K

-2.03%

Ms. Lisa Locklear

Chief Financial Officer, Treasurer

152.42K

-7.23%

Dr. Nataliya Agafonova, M.D.

Chief Medical Officer

140.15K

-7.82%

Mr. Devin Blass

Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls

102.54K

-6.91%

Mr. Khoso Baluch

Independent Director

41.36K

+39.76%

Ms. Ursula Ungaro, J.D.

Independent Director

35.55K

+91.64%

Mr. Richard N. Kender

Independent Director

22.33K

+318.71%

Mr. Roger Joseph Hajjar

Independent Director

21.00K

+425.00%

Ms. Neha Motwani

Independent Director

21.00K

+425.00%

Dr. George Paletta

Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Joshua M. Hare, M.D.

Executive Chairman of the Board, Co-Founder, Chief Science Officer

253.07K

-2.03%

Ms. Lisa Locklear

Chief Financial Officer, Treasurer

152.42K

-7.23%

Dr. Nataliya Agafonova, M.D.

Chief Medical Officer

140.15K

-7.82%

Mr. Devin Blass

Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls

102.54K

-6.91%

Mr. Khoso Baluch

Independent Director

41.36K

+39.76%

Ms. Ursula Ungaro, J.D.

Independent Director

35.55K

+91.64%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

Por EmpresaUSD

Nome

Receita

Proporção

Clinical trial revenue

298.00K

94.30%

Contract manufacturing

12.00K

3.80%

Contract manufacturing lease revenue

6.00K

1.90%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Clinical trial revenue

298.00K

94.30%

Contract manufacturing

12.00K

3.80%

Contract manufacturing lease revenue

6.00K

1.90%

Distribuição de ações

Atualizado em: qua, 29 de out

Investidores

Tipos de investidores

Investidores

Proporção

Lincoln Alternative Strategies LLC

6.01%

Armistice Capital LLC

3.45%

Lehr (Paul T)

1.66%

Hashad (Mohamed Wa'el Ahmed)

1.59%

Hare (Joshua M)

1.29%

Outro

85.99%

Investidores

Proporção

Lincoln Alternative Strategies LLC

6.01%

Armistice Capital LLC

3.45%

Lehr (Paul T)

1.66%

Hashad (Mohamed Wa'el Ahmed)

1.59%

Hare (Joshua M)

1.29%

Outro

85.99%

Tipos de investidores

Investidores

Proporção

Individual Investor

9.26%

Corporation

6.01%

Hedge Fund

3.96%

Investment Advisor

1.66%

Investment Advisor/Hedge Fund

1.09%

Venture Capital

0.25%

Bank and Trust

0.02%

Outro

77.75%

Participação acionária institucional



Atualizado em: dom, 5 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

58

1.37M

6.98%

+569.67K

2025Q2

73

2.18M

16.11%

+296.38K

2025Q1

73

2.14M

15.82%

-119.71K

2024Q4

73

2.53M

18.80%

+652.31K

2024Q3

67

2.33M

17.58%

+1.38M

2024Q2

67

924.88K

16.16%

+194.99K

2024Q1

64

168.05K

15.95%

-258.83K

2023Q4

68

363.47K

37.19%

+110.22K

2023Q3

73

198.13K

31.46%

-72.89K

2023Q2

70

193.49K

31.19%

-39.22K

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Lincoln Alternative Strategies LLC

1.18M

6.01%

+1.18M

--

Aug 08, 2025

Armistice Capital LLC

676.23K

3.45%

+676.23K

--

Sep 30, 2024

Lehr (Paul T)

330.30K

2.42%

+100.44K

+43.69%

Jul 15, 2025

Hashad (Mohamed Wa'el Ahmed)

310.90K

1.59%

+166.85K

+115.83%

Jul 15, 2025

Hare (Joshua M)

253.07K

1.29%

-5.25K

-2.03%

May 16, 2025

Soffer (Rock J)

179.52K

0.92%

+17.00K

+10.46%

Jul 15, 2025

Locklear (Lisa)

164.30K

0.85%

+11.77K

+7.71%

Aug 11, 2025

The Vanguard Group, Inc.

144.27K

0.74%

--

Jun 30, 2025

Geode Capital Management, L.L.C.

141.50K

0.72%

+770.00

+0.55%

Jun 30, 2025

Agafonova (Nataliya)

152.03K

1.12%

+94.57K

+164.57%

Jul 15, 2025

Ver Mais

ETFs Relacionados



Atualizado em: dom, 2 de nov

Nome

Proporção

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Data

Tipo

Proporção

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1